STOCKHOLM, Oct. 27, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026

Third Quarter 2026

Total revenue increased 16 per cent at CER (constant exchange rates), 17 per cent at actual rates, to SEK 9,124 M (7,776), leading to a year-to-date growth of 23 per cent at CER
Haematology revenue increased 29 per cent at CER to SEK 6,171 M (4,771), mainly driven by strong sales of Altuvoct of SEK 1,729 M (769) and of Doptelet of SEK 1,829 M (1,408)
Immunology revenue decreased 6 per cent at CER to SEK 2,525 M (2,658), impacted by lower quarterly revenue from Beyfortus royalties of SEK 732 M (1,166), partially offset by strong sales of Gamifant of SEK 834 M (733) and Kineret of SEK 959 M (769)
Revenue from the strategic portfolio¹ grew by 25 per cent at CER to SEK 6,298 M (5,001)
The adjusted EBITA margin^1,2 was 45 per cent (47), excluding IAC² of SEK 97 M (6,664). EBITA¹ was SEK 3,990 M (3,620), corresponding to a margin of 44 per cent (47). EBIT was SEK 3,226 M (-3,858)
Earnings per share (EPS) before dilution was SEK 6.76 (-8.40) and EPS after dilution was SEK 6.69 (-8.32). Adjusted EPS before dilution¹ was SEK 6.96 (6.11) and adjusted EPS after dilution¹ was SEK 6.89 (6.05)
Cash flow from operating activities was SEK 1,871 M (1,840)
Guido Oelkers to step down as Sobi CEO no later than the end of January 2027
After the quarter, Tryngolza received a positive CHMP opinion for the treatment of sHTG in Europe

Outlook 2026 - Updated

Revenue is anticipated to grow by high-teens to low-20s per cent at CER (previously, mid- to high-teens per cent)
The adjusted EBITA margin is anticipated to be in the mid- to high-30s per cent of revenue (unchanged)

^{1. Alternative Performance Measures (APMs)}^{2. Items affecting comparability (IAC)}

Investors, analysts, and the media are invited to a conference call on the same day at 15:00 CET, 14:00 GMT, and 10:00 EDT. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

HD Web Phone™: click here
Sweden: +46 8 5051 0031
United Kingdom: +44 203 059 58 63
United States: +1 631 570 56 13

For other countries, please find the details here.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on 27 October 2026.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q3-2026-report--underpinning-a-strong-growth-momentum,c4415394

The following files are available for download:


 
 https://mb.cision.com/Main/14266/4415394/4339875.pdf Q3 2026 report. Underpinning a strong growth
                                                          momentum

View original content:https://www.prnewswire.co.uk/news-releases/sobi-q3-2026-report-underpinning-a-strong-growth-momentum-302920465.html

Tags

More Like This

Sobi Q2 2026 report: Significant growth with important pipeline progress

Sobi Q1 2026 report: Strong execution and pipeline momentum

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Sobi Q3 2025 report: Accelerated growth and portfolio momentum

Sobi publishes Q3 2023 report: Strong revenue and solid performance

Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress